We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
I am a board-certified medical oncologist who specializes in treating men with prostate cancer, particularly those who have metastatic disease (disease that has spread to distant organs) or who are at high risk of developing metastatic disease. I am the Prostate Cancer Section Head, which means I lead a group of experts who are dedicated to researching and treating this disease.
Much of my research focuses on drugs that can deliver radioactive molecules targeted specifically to prostate cancer cells or to the distant areas where the cancer spreads. These drugs can be used alone or in combination with other anti-cancer strategies. This research represents a team effort between medical oncologists, nuclear medicine doctors, and radiologists to bring these novel and exciting drugs to the people with prostate cancer who need them.
I am also interested in developing new ways to image prostate cancer using unique, prostate-cancer-specific PET scans and other new imaging methods. This type of imaging not only provides insight into where the prostate cancer is located but informs us about its biology as well. Treatments can then be more precisely and personally tailored to an individual’s disease.
One of my priorities is increasing patient access to clinical trials. I am one of the leaders of the Prostate Cancer Clinical Trials Consortium. This initiative is designed to increase patient access to clinical trials across the country. I also chair the Genitourinary Committee of the National Cancer Institute’s cooperative group Alliance for Clinical Trials in Oncology, which facilitates testing new drugs nationwide. I have been very involved with the American Society of Clinical Oncology, taking various roles centering around prostate cancer and other genitourinary diseases.
My Role at MSK
A genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) oncologist is a cancer doctor with special training in the genitourinary (GU) system. This includes bladder, kidney, penis, prostate, and testicular cancers.
Areas of Expertise
My Specialties
Prostate Cancer
New Investigational Agents
Education & Honors
Education
MD, Mount Sinai School of Medicine
Residencies
Medicine - Columbia Presbyterian Medical Center
Awards and Honors
Top Doctors New York Metro Area, Castle Connolly (2023)
Castle Connolly: America's Top Doctors (2023)
Castle Connolly: New York Magazine Top Doctors (2013
2015-2020)
Fellowships
Oncology/Hematology - Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College
Board Certifications
Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
Aetna
In Network Coverage Type HMO, EPO PPO, POS, Transplant
Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Visit PubMed for a full listing of Dr. Morris’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
We strive to keep reviews trustworthy, honest and fair.
Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael J. Morris discloses the following relationships and financial interests:
Amgen Professional Services and Activities
AstraZeneca Professional Services and Activities
Bayer Professional Services and Activities (Uncompensated)
Blue Earth Diagnostics Professional Services and Activities
Clarity Pharmaceuticals Professional Services and Activities
Convergent Therapeutics, Inc. Professional Services and Activities
Daiichi Sankyo Professional Services and Activities
Doximity, Inc. Equity
ITM Isotopen Technologien München AG Professional Services and Activities
Janssen Research & Development, LLC Professional Services and Activities (Uncompensated)
Lantheus Medical Imaging, Inc. Professional Services and Activities
Novartis Professional Services and Activities (Uncompensated)
POINT Biopharma Global Inc. Professional Services and Activities
Pfizer, Inc. Professional Services and Activities
Progenics Professional Services and Activities
Telix Pharmaceuticals Limited Professional Services and Activities
Z-Alpha, Inc. Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
